QLS7305

QLS7305 is an investigational complement C3 inhibitor being developed by Qilu Pharmaceutical for the treatment of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G). By targeting C3, the central component of the complement cascade, QLS7305 inhibits all three activation pathways (classical, lectin, and alternative), thereby preventing the formation of C3 convertases and the downstream effector molecules like C5 and the membrane attack complex (MAC). This mechanism is intended to control both intravascular and extravascular hemolysis in PNH and reduce inflammatory damage in the kidneys for patients with C3G. The drug is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and pharmacokinetics in healthy participants following subcutaneous administration.